Katsuhiro Yoshikawa1,2, Mitsuaki Ishida3, Hirotsugu Yanai2, Koji Tsuta1, Mitsugu Sekimoto2, Tomoharu Sugie2. 1. Department of Pathology and Clinical Laboratory, Kansai Medical University, 2-5-1, Shinmachi, Osaka, 573-1010, Hirakata City, Japan. 2. Department of Surgery, Kansai Medical University, 2-5-1, Shinmachi, Osaka, Hirakata City, Japan. 3. Department of Pathology and Clinical Laboratory, Kansai Medical University, 2-5-1, Shinmachi, Osaka, 573-1010, Hirakata City, Japan. ishidamt@hirakata.kmu.ac.jp.
Abstract
BACKGROUND: Cancer-associated fibroblasts (CAFs) are some of the most abundant components of the tumour microenvironment. A recent study suggested that in some cancers, CAFs express programmed death ligand 1 (PD-L1), which can act as a prognostic marker. The aim of this study was to investigate the clinicopathological significance of CAF PD-L1 expression in patients with triple-negative breast cancer (TNBC) and to identify the most suitable primary antibody for immunostaining for CAF PD-L1. METHODS: Immunohistochemical staining (primary antibodies of 73-10, SP142, and E1L3N) and tissue microarrays were used to analyse the expression profiles of PD-L1 in CAF in 61 patients with TNBC who underwent surgery. Overall survival (OS) was compared based on CAF PD-L1 expression, and the risk factors for OS were analysed. The relationship between clinicopathological parameters and survival was also examined. RESULTS: Thirty-four (55.7%) patients were positive for CAF PD-L1 (73-10) expression. Compared with CAF PD-L1 negativity, there was a significant correlation between CAF PD-L1 positivity and better OS (p = 0.029). CAF PD-L1 expression, evaluated using SP-142 or E1L3N, did not correlate with OS. CAF PD-L1-positivity (73-10) correlated significantly with better prognosis in multivariate analyses (hazard ratio: 0.198; 95% confidence interval: 0.044-0.891; p = 0.035). CONCLUSIONS: CAF PD-L1 expression is a novel marker for a better prognosis of patients with TNBC, and the 73-10 assay may be suitable for immunostaining CAF PD-L1.
BACKGROUND:Cancer-associated fibroblasts (CAFs) are some of the most abundant components of the tumour microenvironment. A recent study suggested that in some cancers, CAFs express programmed death ligand 1 (PD-L1), which can act as a prognostic marker. The aim of this study was to investigate the clinicopathological significance of CAFPD-L1 expression in patients with triple-negative breast cancer (TNBC) and to identify the most suitable primary antibody for immunostaining for CAFPD-L1. METHODS: Immunohistochemical staining (primary antibodies of 73-10, SP142, and E1L3N) and tissue microarrays were used to analyse the expression profiles of PD-L1 in CAF in 61 patients with TNBC who underwent surgery. Overall survival (OS) was compared based on CAFPD-L1 expression, and the risk factors for OS were analysed. The relationship between clinicopathological parameters and survival was also examined. RESULTS: Thirty-four (55.7%) patients were positive for CAFPD-L1 (73-10) expression. Compared with CAFPD-L1 negativity, there was a significant correlation between CAFPD-L1 positivity and better OS (p = 0.029). CAFPD-L1 expression, evaluated using SP-142 or E1L3N, did not correlate with OS. CAFPD-L1-positivity (73-10) correlated significantly with better prognosis in multivariate analyses (hazard ratio: 0.198; 95% confidence interval: 0.044-0.891; p = 0.035). CONCLUSIONS:CAFPD-L1 expression is a novel marker for a better prognosis of patients with TNBC, and the 73-10 assay may be suitable for immunostaining CAFPD-L1.
Entities:
Keywords:
Cancer-associated fibroblasts; Overall survival; Programmed death ligand 1; Triple-negative breast cancer
Authors: Emad A Rakha; Maysa E El-Sayed; Andrew R Green; Andrew H S Lee; John F Robertson; Ian O Ellis Journal: Cancer Date: 2007-01-01 Impact factor: 6.860
Authors: Fred R Hirsch; Abigail McElhinny; Dave Stanforth; James Ranger-Moore; Malinka Jansson; Karina Kulangara; William Richardson; Penny Towne; Debra Hanks; Bharathi Vennapusa; Amita Mistry; Rasika Kalamegham; Steve Averbuch; James Novotny; Eric Rubin; Kenneth Emancipator; Ian McCaffery; J Andrew Williams; Jill Walker; John Longshore; Ming Sound Tsao; Keith M Kerr Journal: J Thorac Oncol Date: 2016-11-29 Impact factor: 15.609
Authors: Oliver Treacy; Kevin Lynch; Serika D Naicker; Grace O'Malley; Niamh A Leonard; Paul Lohan; Philip D Dunne; Thomas Ritter; Laurence J Egan; Aideen E Ryan Journal: Cancer Immunol Res Date: 2018-09-18 Impact factor: 11.151